Targeted Site-Specific Therapeutics for COVID-19

No definitive therapies for COVID-19 have yet to be identified. The several hundred planned or ongoing clinical trials globally will provide some insights into therapies that may or may not work. The overwhelming majority of therapeutics rely on the systemic delivery of drugs, however, COVID-19 is largely localized to the lungs with some subgroups afflicted in other organ systems. We propose the use of a targeted drug delivery approach in which therapeutics can be delivered using engineered delivery vehicles to reach damaged lung tissue directly.